Novelion Therapeutics Inc. (NVLN) and Aytu BioScience Inc. (NASDAQ:AYTU) Comparison side by side

Both Novelion Therapeutics Inc. (NASDAQ:NVLN) and Aytu BioScience Inc. (NASDAQ:AYTU) are Biotechnology companies, competing one another. We will compare their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novelion Therapeutics Inc. 135.15M 0.12 107.35M -5.76 0.00
Aytu BioScience Inc. 6.53M 4.62 12.05M -7.14 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 demonstrates the return on equity, return on assets and net margins of Novelion Therapeutics Inc. and Aytu BioScience Inc.

Net Margins Return on Equity Return on Assets
Novelion Therapeutics Inc. -79.43% 210.1% -33.2%
Aytu BioScience Inc. -184.53% -73.8% -39.6%

Risk and Volatility

Novelion Therapeutics Inc. has a 2.19 beta, while its volatility is 119.00%, thus making it more volatile than S&P 500. Competitively, Aytu BioScience Inc.’s 367.00% volatility makes it more volatile than S&P 500, because of the 4.67 beta.


The Current Ratio of Novelion Therapeutics Inc. is 0.2 while its Quick Ratio stands at 0.2. The Current Ratio of rival Aytu BioScience Inc. is 4.7 and its Quick Ratio is has 4.4. Aytu BioScience Inc. is better equipped to clear short and long-term obligations than Novelion Therapeutics Inc.

Insider and Institutional Ownership

Roughly 51.2% of Novelion Therapeutics Inc. shares are owned by institutional investors while 40.1% of Aytu BioScience Inc. are owned by institutional investors. 0.2% are Novelion Therapeutics Inc.’s share owned by insiders. Comparatively, insiders own roughly 2.7% of Aytu BioScience Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Novelion Therapeutics Inc. -3.61% -16.67% -13.04% -29.82% -70.66% 42.86%
Aytu BioScience Inc. -10.34% 5.06% 85.71% 122.17% -73.6% 162.49%

For the past year Novelion Therapeutics Inc. has weaker performance than Aytu BioScience Inc.


Novelion Therapeutics Inc. beats Aytu BioScience Inc. on 6 of the 10 factors.

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases. Its product portfolio includes MYALEPT (metreleptin), a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; and lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the brand names of JUXTAPID and LOJUXTA. The companyÂ’s orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, in late stage development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of urology in the United States. The company markets Natesto for the treatment of hypogonadism (low testosterone) in men; and ProstaScint for use in newly diagnosed high-risk prostate cancer patients and patients with recurrent prostate cancer. It is also involved in commercializing of the RedoxSYS System for research use in various applications. In addition, the company is developing MiOXSYS, an in vitro diagnostic semen analysis test that is used in the quantitative measurement of static oxidation reduction potential in human semen. Further, the company provides Fiera personal care device, a hands-free wearable product for women that is designed to enhance interest in and physical readiness for sex. Aytu BioScience, Inc. is based in Englewood, Colorado.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.